nach oben

Clinical & Experimental Metastasis

Erschienen in:

17.12.2016 | Review

Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons

verfasst von: Tapas Das, Sharmila Banerjee

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Bone pain arising due to skeletal metastases is one of the common complications experienced by the majority of patients suffering from prostate, breast and lung cancer at the advanced stage of the disease. These patients are subjected to palliative care in order to improve the quality of their remaining life. With the gradually increasing number of cancer cases, palliation of metastatic bone pain is gaining importance. Bone-seeking radiopharmaceuticals play a pivotal role in the management of cancer pain, particularly in patients with multiple metastases, as these agents are proven to be effective in controlling the bone pain with minimum side effects. Although a plethora of such radiopharmaceuticals have been developed and evaluated in animal models, only a few are regularly used in clinics while some of these agents are at different stages of clinical evaluations. The present article describes only those bone-seeking radiopharmaceuticals, which have been reported to be clinically administered till date, along with their relative merits and drawbacks.

Palma E, Correia JDG, Campello MPC, Santos I (2011) Bisphosphonates as radionuclide carriers for imaging or systemic therapy. Mol Biosyst 7:2950–2966CrossRefPubMed

Mertens WC, Filipczak LA, Ben-Josef E, Davis LP, Porter AT (1998) Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. CA Cancer J Clin 48:361–374CrossRefPubMed

Garrett IR (1993) Bone destruction in cancer. Semin Oncol 20(Suppl 2):4–9PubMed

Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163–174CrossRefPubMed

Selvaggi G, Scagliotti GV (2005) Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol 56:365–378CrossRefPubMed

Greco C, Forte L, Erba P, Mariani G (2011) Bone metastases, general and clinical issues. Quart J Nucl Med Mol Imaging 55:337–352

DeNardo GL (1998) Bone pain palliation. Cancer Biother Radiopharm 13:407–411CrossRefPubMed

Paes FM, Serafini AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 40:89–104CrossRefPubMed

Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, Giammarile F (2008) EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging 35:1934–1940CrossRefPubMed

10.

Li BT, Wong WT, Pavlakis N (2014) Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice. J Clin Med 3:1–24CrossRefPubMedPubMedCentral

11.

Lewington VJ (2005) Bone-seeking radionuclides for therapy. J Nucl Med 46:38S–47SPubMed

12.

Volkert WA, Hoffman TJ (1999) Therapeutic radiopharmaceuticals. Chem Rev 99:2269–2292CrossRefPubMed

13.

Guerra Liberal FDC, Tavares AAS, Tavares JMRS (2014) Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods. Med Phys. doi:10.1118/1.4897240 PubMed

14.

Vats K, Das T, Sarma HD, Banerjee S, Pillai MRA (2013) Radiolabeling, stability studies and pharmacokinetic evaluation of Thulium-170-labeled acyclic and cyclic polyaminopolyphosphonic acids. Cancer Biother Radiopharm 28:737–745CrossRefPubMed

15.

Giammarile F, Mognetti T, Resche I (2001) Bone pain palliation with strontium-89 in cancer patients with bone metastases. Quart J Nucl Med 45:78–83

16.

Finlay IG, Mason MD, Shelley M (2005) Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6:392–400CrossRefPubMed

17.

Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Winston D (1987) Skeletal localisation of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28:495–504PubMed

18.

Jurisson S, Berning D, Jia W, Ma D (1993) Coordination compounds in nuclear medicine. Chem Rev 93:1137–1156CrossRef

19.

Das T, Chakraborty S, Unni PR, Banerjee S, Samuel G, Sarma HD, Venkatesh M, Pillai MRA (2002) ¹⁷⁷Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot 57:177–184CrossRefPubMed

20.

Harrison MR, Wong TZ, Armstrong AJ, George DJ (2013) Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 5:1–14CrossRefPubMedPubMedCentral

21.

Abi-Ghanem AS, McGrath MA, Jacene HA (2015) Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med 45:66–80CrossRefPubMed

22.

Shirley M, McCormack PL (2014) Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 74:579–586CrossRefPubMed

23.

Vengalil S, O’Sullivan JM, Parker CC (2012) Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care 6:310–315CrossRefPubMed

24.

Parker C, Heinrich D, O’Sullivan JM, Fossa S, Chodacki A, Demkow T, Cross A, Bolstad B, Garcia-Vargas J, Sartor O (2011) Overall survival benefit of radium-223 chloride (alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 47(Suppl 2):3CrossRef

25.

Maini CL, Sciuto R, Romano L, Bergomi S (2003) Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. J Exp Clin Cancer Res 22(4 Suppl):71–74PubMed

26.

Lewington VJ (1993) Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20:66–74CrossRefPubMed

27.

Bauman G, Charette M, Reid R, Sathya J (2005) Radiopharmaceuticals for the palliation of painful bone metastasis—a systemic review. Radiother Oncol 75:258–270CrossRefPubMed

28.

Ogawa K, Washiyama K (2012) Bone target radiotracers for palliative therapy of bone metastases. Curr Med Chem 19:3290–3300CrossRefPubMed

29.

Guerra Liberal FDC, Tavares AAS, Tavares JMRS (2016) Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153. Appl Radiat Isot 110:87–99CrossRefPubMed

30.

Friedell HL, Storaasli JP (1950) The use of radioactive phosphorus in the treatment of carcinoma of the breast with widespread metastases to bone. AJR Am J Roentgenol 64:559–575

31.

Silberstein EB (1993) The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 20(suppl 2):10–21PubMed

32.

Silberstein EB, Buscombe JR, Taylor AT Jr (2003) Society of nuclear medicine procedure guideline for palliative treatment of painful bone metastases. Soc Nucl Med Proced Guidel Man 147–154

33.

Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365PubMed

34.

Das T, Pillai MRA (2013) Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 40:23–32CrossRefPubMed

35.

Vimalnath KV, Shetty P, Chakraborty S, Das T, Chirayil V, Sarma HD, Jagadeesan KC, Joshi PV (2013) Practicality of production of ³²P by direct neutron activation for its utilization in bone pain palliation as Na₃[³²P]PO₄. Cancer Biother Radiopharm 28:423–428CrossRefPubMed

36.

Atkins HL (1998) Overview of nuclides for bone pain palliation. Appl Radiat Isot 49:277–283CrossRefPubMed

37.

Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31:330–341CrossRefPubMed

38.

Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454PubMed

39.

Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL (2001) Metastatic bone pain palliation with ⁸⁹Sr and ¹⁸⁶Re-HEDP in breast cancer patients. Br Cancer Res Treat 66:101–109CrossRef

40.

Bos SD (1994) An overview of current clinical experience with Strontium-89 (Metastron^®). Prostate 25:23–26CrossRef

41.

Das T, Chakraborty S, Sarma HD, Tandon P, Banerjee S, Venkatesh M, Pillai MRA (2009) ¹⁷⁰Tm-EDTMP: a potential cost-effective alternative to ⁸⁹SrCl₂ for bone pain palliation. Nucl Med Biol 36:561–568CrossRefPubMed

42.

Kostadinova I, Pavlova A, Chakarova A, Petkova E (2006) Which is better and more effective to use in patients with painful bone metastasis–⁸⁹Sr or ³²P. Rentgenol i Radiol 43:67–68

43.

Resche I, Chatal JF, Pecking A, Ell PJ, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of ¹⁵³Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591CrossRefPubMed

44.

Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–1581PubMed

45.

Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940–945CrossRefPubMed

46.

Serafini AN (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 88:2934–2939CrossRefPubMed

47.

Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F (1993) Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34:1031–1036PubMed

48.

Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34:1839–1844PubMed

49.

Chakraborty S, Das T, Banerjee S, Chaudhari PR, Sarma HD, Venkatesh M, Pillai MRA (2004) Preparation and biological evaluation of ¹⁵³Sm-DOTMP as a potential agent for bone pain palliation. Nucl Med Commun 25:1169–1176CrossRefPubMed

50.

Ramamoorthy N, Saraswathy P, Das MK, Mehra KS, Ananthakrishnan M (2002) Production logistics and radionuclidic purity aspects of ¹⁵³Sm for radionuclide therapy. Nucl Med Commun 23:83–89CrossRefPubMed

51.

Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF Jr, Biersack HJ (2000) Dose escalation study with Rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123–130CrossRefPubMed

52.

Biersack HJ, Palmedo H, Andris A, Rogenhofer S, Knapp FF Jr, Guhlke S, Ezziddin S, Bucerius J, von Mallek D (2011) Palliation and survival after repeated ¹⁸⁸Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 52:1721–1726CrossRefPubMed

53.

Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IGH, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869–2875CrossRefPubMed

54.

Cheng A, Chen S, Zhang Y, Yin D, Dong M (2011) The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer Biother Radiopharm 26:237–244CrossRefPubMed

55.

Jeong JM, Chung JK (2003) Therapy with ¹⁸⁸Re-labeled radiopharmaceuticals: an overview of promising results from initial clinical trials. Cancer Biother Radiopharm 18:707–717CrossRefPubMed

56.

Boschi A, Uccelli L, Pasquali M, Duatti A, Taibi A, Pupillo G, Esposito J (2014) ¹⁸⁸W/¹⁸⁸Re generator system and its therapeutic applications. J Chem (Article number 529406)

57.

Pillai MRA, Dash A, Knapp FF Jr (2012) Rhenium-188: availability from the ¹⁸⁸W/¹⁸⁸Re generator and status of current applications. Curr Radiopharm 5:228–243CrossRefPubMed

58.

Verdera ES, Gaudiano J, Leon A, Martinez G, Robles A, Savio E, Leon E, McPherson DW, Knapp FF Jr (1997) Rhenium-188-HEDP-kit formulation and quality control. Radiochim Acta 79:113–117CrossRef

59.

Mallia MB, Shinto AS, Kameswaran M, Kamaleshwaran KK, Radhakrishnan K, Aswathy KK, Banerjee S (2016) A freeze-dried kit for the preparation of ¹⁸⁸Re-HEDP for bone pain palliation: preparation and preliminary clinical evaluation. Cancer Biother Radiopharm 31:139–144CrossRefPubMed

60.

Knapp FF Jr, Mirzadeh S, Garland M, Ponsard B, Kuznetzov R (2010) Reactor production and processing of ¹⁸⁸W. Production of long-lived parent radionuclides for generators: ⁶⁸Ge, ⁸²Sr, ⁹⁰Sr and ¹⁸⁸W. IAEA:79–109, ISBN: 978-92-0-101110-7. http://www-pub.iaea.org/MTCD/publications/PubDetails.asp?pubId = 8268. Accessed 10 Dec 2016

61.

Maxon HR III, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R, Scher HI, Moulton JS, Deutsch EA, Deutsch KF, Schneider HJ, Williams CC (1992) Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 2:33–40CrossRef

62.

Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS (2009) Management of metastatic bone pain with repeated doses of rhenium-186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice. Cancer Biother Radiopharm 24:543–550CrossRefPubMed

63.

Van Dodewaard-De Jong JM, de Klerk JMH, Bloemendal HJ, Van Bezooijen BPJ, de Haas MJ, Wilson RH, O’Sullivan JM (2011) A phase I study of combined docetaxel and repeated high activity ¹⁸⁶Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial). Eur J Nucl Med Mol Imaging 38:1990–1998CrossRefPubMed

64.

Pirayesh E, Amoui M, Mirzaee HR, Tabei F, Rakhsha A, Kalantari BA, Shafiei B, Assadi M, Asli IN (2013) Phase 2 study of a high dose of ¹⁸⁶Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. J Nucl Med Technol 41:192–196CrossRefPubMed

65.

Srivastava SC, Meinken GE, Richards P, Som P, Oster ZH, Atkins HL, Brill A, Knapp FF Jr, Butler TA (1985) The development and in vivo behavior of tin-containing radiopharmaceuticals: I. Chemistry, preparation and distribution in small animals. Int J Nucl Med Biol 12:l67–174CrossRef

66.

Oster ZH, Som P, Srivastava SC, Fairchild RG, Meinken GE, Tillman DY, Sacker DF, Richards P, Atkins HL, Brill AB (1985) The development and in vivo behavior of tin-containing radiopharmaceuticals: II. Autoradiographic and scintigraphic studies in normal animals and animal model of bone disease. Int J Nucl Med Biol 12:175–184CrossRefPubMed

67.

Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Straub RF, Cabahug CJ, Weber DA, Wong CT, Sacker DF, Madajewicz S (1993) Biodistribution of Sn-l17m(4+)DTPA for palliation therapy of painful osseous metastases. Radiology 186:279–283CrossRefPubMed

68.

Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D’Alessandro T (1995) Sn-117m(4+)DTPA for palliation of painful osseous metastases: a pilot study. J Nucl Med 36:725–729PubMed

69.

Krishnamurthy GT, Swailem FM, Srivastava SC, Atkins HL, Simpson LJ, Walsh KT, Ahmann FR, Meinken GE, Shah JH (1997) Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med 38:230–237PubMed

70.

Srivastava SC, Atkins HL, Krishnamurthy GT, Zanzi I, Silberstein EB, Meinken G, Mausner LF, Swailem F, D’Alessandro T, Cabahug CJ, Lau Y, Park T, Madajewicz S (1998) Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 4:61–68PubMed

71.

Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bloch WE, Howel RW (2000) Marrow sparing effects of 117mSn(4+) diethylenetriaminepentaacetic acid for radionuclidic therapy of bone cancer. J Nucl Med 41:2043–2050PubMed

72.

Manuel for reactor produced isotopes. IAEA (2003) Vienna, Austria. http://www.isotopes.gov/outreach/reports/Reactor_Isotopes.pdf. Accessed 10 Dec 2016

73.

Srivastava SC (2013) A bridge not too far: personalized medicine with the use of Theragnostic Radiopharmaceuticals. J Postgrad Med Educ Res 47:31–46CrossRef

74.

Maslov OD, Starodub GY, Vostokin GK, Gustova MV, Dmitriev SN, Shvetsov VN, Szucs Z, Jansen D, Zeevaart JR (2011) Production of Sn-117m with high specific activity by cyclotron. Appl Radiat Isot 69:965–968CrossRefPubMed

75.

Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ (2013) Efficacy and safety of ¹⁷⁷Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 38:88–92CrossRefPubMed

76.

Agarwal KK, Singla S, Arora G, Bal CS (2015) ¹⁷⁷Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 42:79–88CrossRefPubMed

77.

Shinto AS, Shibu D, Kamaleshwaran KK, Das T, Chakraborty S, Banerjee S, Thirumalaisamy P, Das P, Veersekar G (2014) ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol 42:55–61CrossRefPubMed

78.

Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S (2015) Clinical efficacy and safety comparison of ¹⁷⁷Lu-EDTMP with ¹⁵³Sm-EDTMP on an equidose basis in patients with painful skeletal metastases. J Nucl Med 56:1513–1519CrossRefPubMed

79.

Pillai MRA, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N (2003) Production logistics of ¹⁷⁷Lu for radionuclide therapy. Appl Radiat Isot 59:109–118CrossRefPubMed

80.

Banerjee S, Das T, Chakraborty S, Venkatesh M (2012) Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. Radiochim Acta 100:115–126CrossRef

81.

Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, Polyák A, Máthé D, Venkatesh M, Janoki G, Pillai MRA (2008) ¹⁷⁷Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm 23:202–213CrossRefPubMed

82.

Das T, Sarma HD, Shinto A, Kamaleshwaran KK, Banerjee S (2014) Formulation, pre-clinical evaluation and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of ¹⁷⁷Lu-EDTMP. Cancer Biother Radiopharm 29:412–421CrossRefPubMed

83.

Garnuszek P, Pawlak D, Licińska I, Kamińska A (2003) Evaluation of a freeze-dried kit for EDTMP-based bone-seeking radiopharmaceuticals. Appl Radiat Isot 58:481–488CrossRefPubMed

84.

Bruland ØS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter ²²³Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12:6250s–6257sCrossRefPubMed

85.

Ritter MA, Cleaver JE, Tobias CA (1977) High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 266:653–655CrossRefPubMed

86.

Bruland ØS, Jonasdottir TJ, Fisher DR, Larsen RH (2008) Radium-223: from radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm 1:203–208CrossRef

87.

Henriksen G, Breistol K, Bruland ØS, Fodstad O, Larsen RH (2002) Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 62:3120–3125PubMed

88.

van Leeuwen FW, Verboom W, Reinhoudt DN (2005) Selective extraction of naturally occurring radioactive Ra²⁺. Chem Soc Rev 34:753–761CrossRefPubMed

89.

Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland ØS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451–4459CrossRefPubMed

90.

Wissing MD, van Leeuwen FWB, van der Pluijm G, Gelderblom H (2013) Radium-223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res 19:5822–5827CrossRefPubMed

91.

Vaidyanathan G, Zalutsky MR (2011) Applications of ²¹¹At and ²²³Ra in targeted alpha-particle radiotherapy. Curr Radiopharm 4:283–294CrossRefPubMedPubMedCentral

92.

Henriksen G, Alstad J, Hoff P, Larsen RH (2001) ²²³Ra for endotherapeutic applications prepared from an immobilized ²²⁷Ac/²²⁷Th source. Radiochim Acta 89:661–666CrossRef

93.

Shirvani-Arani S, Bahrami-Samani A, Meftahi M, Jalilian AR, Ghannadi-Maragheh M (2013) Production, quality control and biodistribution studies of thulium-170-labeled ethylenediamine (tetramethylene phosphonic acid). Radiochim Acta 101:37–43CrossRef

94.

Sahiralamkhan M, Chakravarty R, Chakraborty S, Kamaleshwaran KK, Shinto A, Dash A (2016) Irradiation parameters play a crucial role in the (n,γ) production of ¹⁷⁰Tm suitable for clinical use in bone pain palliation. J Radioanal Nucl Chem 307:1105–1113CrossRef

95.

Liu S, Edwards DS (2001) Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj Chem 12:7–34CrossRef

96.

Banerjee S, Pillai MRA, Knapp FF Jr (2015) Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 115:2934–2974CrossRefPubMed

97.

Das T, Chakraborty S, Sarma HD, Banerjee S (2008) ¹⁷⁷Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 96:55–61

98.

Das T, Chakraborty S, Sarma HD, Banerjee S (2015) Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale ¹⁷⁷Lu-DOTMP and ¹⁵³Sm-DOTMP at the hospital radiopharmacy. Radiochim Acta 103:595–604CrossRef

99.

Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S (2008) Comparative studies of ¹⁷⁷Lu-EDTMP and ¹⁷⁷Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 66:1196–1205CrossRefPubMed

100.

Bryan ME, Lattimer JC, Henry CJ, Engelbrecht H, Ketring A, Cutler C (2009) Comparison of systemic toxicities of ¹⁷⁷Lu-DOTMP and ¹⁵³Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. J Nucl Med Technol 37:45–52CrossRefPubMed

101.

Das T, Shinto A, Kamaleshwaran KK, Banerjee S (2016) Theranostic treatment of metastatic bone pain with ¹⁷⁷Lu-DOTMP. Clin Nucl Med 41:966–967CrossRefPubMed

102.

Lange R, ter Heine R, Knapp FF, de Klerk JMH, Bloemendal HJ, Hendrikse HN (2016) Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases. Bone 91:159–179CrossRefPubMed

Titel: Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons
verfasst von: Tapas Das
Sharmila Banerjee
Publikationsdatum: 17.12.2016
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 1/2017
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-016-9831-9

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons

Abstract

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients

Evaluation of miR-21 and miR-375 as prognostic biomarkers in oesophageal cancer in high-risk areas in China

Melanoma cell metastasis via P-selectin-mediated activation of acid sphingomyelinase in platelets

Bif-1 promotes tumor cell migration and metastasis via Cdc42 expression and activity

Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases

The prognostic effect of DDX3 upregulation in distant breast cancer metastases

Neu im Fachgebiet Onkologie

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Update Onkologie